此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Explore Neural Mechanism of Obsessive-Compulsive Disorder (OCD) by Intervention of Repetitive Transcranial Magnetic Stimulation With Symptom Provocation

2026年7月2日 更新者:Taipei Veterans General Hospital, Taiwan

The purpose of this study is to investigate the differences in therapeutic efficacy of different deep Transcranial Magnetic Stimulation (deep TMS) treatment coils and different brain stimulation targets on obsessive-compulsive symptoms, and to explore the neural mechanisms of obsessive-compulsive disorder using functional neuroimaging analysis.

  1. Inclusion Criteria:

    Adults aged 18-65 years. Patients diagnosed with obsessive-compulsive disorder according to DSM-5 criteria.

  2. Study Design: Double-blind, randomized assignment.
  3. Number of Participants:

    Sham group: 32 participants Active H7 group: 32 participants Active H1 group: 32 participants Total: 96 participants

  4. Study Procedures:

    - Participant Screening and Baseline Assessment (Week 0) Determine eligibility for enrollment, including diagnostic confirmation, symptom assessment, screening for contraindications, and whether the participant has previously experienced adverse effects following TMS treatment. Participants with high suicide risk within the past year will be excluded.

    Develop a personalized symptom provocation procedure for obsessive-compulsive symptoms.

    Complete baseline symptom severity assessments and brain positron emission tomography/magnetic resonance imaging (PET/MRI). Participants with structural brain abnormalities will be excluded.

    Participants will be randomly assigned (1:1:1) into three groups, with a planned total enrollment of 96 participants.

    Participants currently taking medication may continue their existing regimen, but no medication changes will be allowed during the study period.

    - Treatment Phase (Week 1 to Week 6; duration: 6 weeks) Before each TMS session, participants will remove their shoes and socks, rest both hands flat on their thighs, keep their eyes looking straight ahead, and undergo measurement of resting motor threshold (RMT).

    Approximately 3-5 minutes before each TMS session, trained personnel with Exposure and Response Prevention (ERP) experience will assist participants in symptom provocation and record the participant's subjective level of distress.

    The deep TMS treatment schedule consists of five sessions per week, one session per day, for six consecutive weeks. Adverse effects will be assessed and monitored at each session.

    After completing the first treatment session, participants will be asked to guess which group they were assigned to, in order to evaluate the effect of treatment expectations on outcomes.

    Symptom severity interviews will be conducted every two weeks.

    - Post-treatment Assessment and Follow-up (Week 7 and after; duration: 2 weeks, then 6 months later) Within one week after completion of the deep TMS treatment course (within Week 7), participants will undergo follow-up brain PET/MRI.

    At the end of Week 8 (two weeks after treatment completion), symptom severity will be reassessed. Subsequent treatment plans will be discussed with participants, and outpatient follow-up will be arranged within six months.

    Subsequent treatment options may include cognitive behavioral therapy, pharmacotherapy, and figure-8 rTMS.

  5. Statistical Analysis

    • Expected Outcomes:

The H7 coil may improve obsessive-compulsive symptoms. Both the H7 and H1 coils may improve mood symptoms.

- Descriptive and Inferential Statistics: Analysis of covariance (ANCOVA) will be used to compare differences among the three groups in Montgomery-Asberg Depression Rating Scale (MADRS), Yale-Brown obsessive compulsive scale (Y-BOCS), Hamilton Anxiety Scale (HAM-A), Hamilton Depression Scale (HDRS), and Clinical Global Impression (CGI-S) scores.

The percentage of responders (% responders) will be calculated and compared among groups.

Repeated-measures ANOVA will be used to examine within-group and between-group differences in symptom improvement before and after deep TMS treatment.

Pearson correlation analysis will be used to assess the association between symptom improvement and changes observed in PET/MRI neuroimaging measures.

- PET/MRI Neuroimaging Analysis: Functional MRI analyses will include ROI-to-ROI functional connectivity and seed-based functional connectivity analyses.

Changes in PET glucose uptake within specific regions of interest (ROIs) will also be examined to evaluate alterations in neural networks and brain function before and after deep TMS treatment.

研究概览

研究类型

介入性

注册 (估计的)

96

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Adults aged 18-65 years.
  • Diagnosis of obsessive-compulsive disorder according to DSM-5 criteria. Treatment resistance (i.e., inadequate response to pharmacological or non-pharmacological treatments) is not required.
  • Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥ 14, indicating at least mild to moderate symptom severity.

Exclusion Criteria:

  • Diagnosis of schizophrenia, organic psychotic disorder, bipolar disorder, alcohol use disorder, or substance use disorder.
  • High suicide risk within the past year.
  • Presence of significant medical or surgical conditions in an active phase.
  • History of, or planned, neurosurgical procedures, or presence of metallic implants in the brain or body (e.g., neurostimulators or cardiac pacemakers).
  • Structural brain abnormalities (e.g., brain tumor or arteriovenous malformation) or neurological disorders (e.g., meningitis, encephalitis, stroke, or epilepsy).
  • Pregnant women.
  • Inability to tolerate PET/MRI examination due to claustrophobia or severe anxiety in confined spaces.
  • Any other conditions that may impair study compliance, including inability to cooperate, failure to provide informed consent, or other investigator-determined ineligibility after screening.
  • Use of medications that may increase seizure risk or suicide risk (e.g., certain antidepressants or antipsychotics).
  • Known allergy to 18F-FDG (18F-2-Fluoro-2-DeoxyGlucose).
  • History of adverse reaction to TMS or allergy to the positioning cap.
  • Presence of metallic objects within approximately 30 cm of the cranial region (within the stimulation coil area).
  • Prior or current treatment with electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Active H7 coil stimulation

Sham dTMS Participants will receive sham deep TMS using a sham coil.

H7 dTMS Participants will receive active deep TMS using the H7 coil.

H1 dTMS Participants will receive active deep TMS using the H1 coil.

假比较器:Sham stimulation group

Sham dTMS Participants will receive sham deep TMS using a sham coil.

H7 dTMS Participants will receive active deep TMS using the H7 coil.

H1 dTMS Participants will receive active deep TMS using the H1 coil.

实验性的:Active H1 coil group

Sham dTMS Participants will receive sham deep TMS using a sham coil.

H7 dTMS Participants will receive active deep TMS using the H7 coil.

H1 dTMS Participants will receive active deep TMS using the H1 coil.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
the percentage changes in Y-BOCS scores after treatments
大体时间:the 6-week and 8-week

Two time-spans are assessed: (a) from baseline (Week 0, W0) to posttreatment (Week 6, W6), and (b) from baseline (W0) to the 2-week follow-up (Week 8, W8). The percentage changes in Y-BOCS scores will be calculated as follows:

  1. percent of YBOCS6-0 = (W6 - W0) / W0
  2. percent of YBOCS8-0 = (W8 - W0) / W0 A full treatment response, defined as a ≥30 percent reduction in Y-BOCS score from baseline, will be evaluated at both the 6-week and 8-week time points.
the 6-week and 8-week

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月22日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年5月8日

首先提交符合 QC 标准的

2026年5月8日

首次发布 (实际的)

2026年5月14日

研究记录更新

最后更新发布 (实际的)

2026年7月6日

上次提交的符合 QC 标准的更新

2026年7月2日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 2024-06-004C

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Patient privacy

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅